EUVIMEDEUVIMED entdecken
Systematische ÜbersichtFallbericht

A systematic review of Janus kinase inhibitors and spleen tyrosine kinase inhibitors for Hidradenitis suppurativa treatment

Amirhossein Heidari, Yekta Ghane, Nazila Heidari, Sara Sadeghi, Azadeh Goodarzi

International Immunopharmacology · 2024-01 · 127 · 111435

DOI: 10.1016/j.intimp.2023.111435 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift International Immunopharmacology, 2024-01. Verfasst von Amirhossein Heidari und 4 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. Electronic address: amirhosseinheidari.md@gmail.com. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa, Janus Kinase Inhibitors, Aminopyridines, Pyrazoles. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 53 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUNDS AND AIMS: Hidradenitis suppurativa (HS) is a challenging skin disease with an underlying inflammatory process. Substantial progress has been made in our understanding of HS over the last few years, with the advancement of novel treatment approaches. The current systematic review aims to evaluate the safety and efficacy of Janus kinase (JAK) inhibitors and spleen tyrosine kinase (Syk) inhibitors in treating HS. METHOD: A thorough systematic search was performed on PubMed/Medline, Web of Science, and Ovid Embase databases up to September 23th, 2023. Clinical studies published in English were included. RESULTS: Our search yielded ten articles with a total of 165 patients treated with four types of JAK inhibitors (upadacitinib, povorcitinib, tofacitinib, and baricitinib) and one Syk inhibitor (fostamatinib). Upadacitinib, povorcitinib, and tofacitinib improved clinical outcomes, with a significant reduction in hidradenitis suppurativa clinical response (HiSCR) and abscess and inflammatory nodule count (AN count) during the treatment period. Also, these drugs are well tolerated in most HS patients with minimal adverse events (AEs). Moreover, baricitinib depicted an amelioration in signs and symptoms of HS in one case report. Also, fostamatinib exhibited favorable tolerability throughout a 12-week in moderate-to-severe HS patients. The remarkable clinical improvement, as assessed through HiSCR and hidradenitis suppurativa severity (IHS4), corresponded closely with serological indicators of inflammation following fostamatinib administration was achieved. CONCLUSION: JAK and Syk inhibitors are potentially efficacious in managing moderate-to-severe HS since the proinflammatory cytokines are mediated by JAK and Syk signaling pathways. However, further research with a more rigorous examination is mandatory to evaluate such medication's long-term safety and efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hidradenitis SuppurativaJanus Kinase InhibitorsAminopyridinesPyrazolesSulfonamidesAzetidinesPurinesPyrimidinesMorpholinesHumansAdalimumabTyrosine Kinase InhibitorsSpleenSyk KinaseTreatment OutcomeSeverity of Illness Index

Stichwörter der Autor:innen

HSHidradenitis suppurativaJAK inhibitorJanus kinase inhibitorSpleen tyrosine kinase inhibitorSyk inhibitor

Substanzen

fostamatinibbaricitinibAdalimumabJanus Kinase InhibitorsTyrosine Kinase InhibitorsSyk KinaseAminopyridinesPyrazolesSulfonamidesAzetidines

Autor:innen und Institutionen

  • Faculty of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. Electronic address: amirhosseinheidari.md@gmail.com.
  • School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: yektaghanemd@gmail.com.
  • School of Medicine, Iran University of Medical Sciences, Tehran, Iran. Electronic address: Nazila.heidari@yahoo.com.
  • Department of Dermatology, Rasool Akram Medical Complex Clinical Research Development Center (RCRDC), School of Medicine, Iran University of Medical Sciences, Tehran, Iran; Department of Medicine, New York Health System…
  • Department of Dermatology, Rasool Akram Medical Complex Clinical Research Development Center (RCRDC), School of Medicine, Iran University of Medical Sciences, Tehran, Iran. Electronic address: Azadeh_goodarzi1984@yahoo.…

Zitieren

APA

Heidari, A., Ghane, Y., Heidari, N., Sadeghi, S., & Goodarzi, A. (2024). A systematic review of Janus kinase inhibitors and spleen tyrosine kinase inhibitors for Hidradenitis suppurativa treatment. International Immunopharmacology, 127, 111435. https://doi.org/10.1016/j.intimp.2023.111435

Vancouver

Heidari A, Ghane Y, Heidari N, Sadeghi S, Goodarzi A. A systematic review of Janus kinase inhibitors and spleen tyrosine kinase inhibitors for Hidradenitis suppurativa treatment. International Immunopharmacology. 2024;127:111435. doi:10.1016/j.intimp.2023.111435

BibTeX
@article{Heidari2024,
  author = {Heidari, Amirhossein and Ghane, Yekta and Heidari, Nazila and Sadeghi, Sara and Goodarzi, Azadeh},
  title = {A systematic review of Janus kinase inhibitors and spleen tyrosine kinase inhibitors for Hidradenitis suppurativa treatment},
  journal = {International Immunopharmacology},
  year = {2024},
  volume = {127},
  pages = {111435},
  doi = {10.1016/j.intimp.2023.111435}
}
Kostenlos starten →